Trial Profile
To assess the risk of diabetes in RA patients using TNFi with or without nbDMARD and with or without corticosteroids using Quebec health services administrative data
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 20 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management